EDUCATION > Courses and Products > E-Learning > Videos/Webcasts > 2012 Annual Meeting Webcasts > The Medical Management of BPH > Module 3: Medical Treatment Using Antimuscarinics

Module 3: Medical Treatment Using Antimuscarinics

Learning Objectives

After participating in this activity, participants should be able to:

  • realize the benefit of and need for differentiated medical therapy of men with LUTS and BPH
  • distinguish mechanisms of action of commonly used drugs for LUTS and BPH
  • describe the treatment options for men with minimally symptomatic BPH

Faculty/Authors

Claus G. Roehrborn, MD
Professor and Chair, Department of Urology
UT Southwestern Medical Center at Dallas
Dallas, TX
Disclosures: Roehrborn, Claus: GlaxoSmithKline: Consultant/Advisor

Christopher Chapple, BSc, MD, FRCS (Urol)
Honorary Senior Lecturer of Urology, University of Sheffield
Consultant Urological Surgeon, Royal Hallamshire Hospital
Sheffield, United Kingdom
Disclosures: Chapple, Christopher R.: Pfizer: Consultant or Advisor,Meeting Participant or Lecturer,Scientific Study or Trial ; Recordati: Consultant or Advisor,Meeting Participant or Lecturer,Scientific Study or Trial ; Astellas: Consultant or Advisor,Meeting Participant or Lecturer,Scientific Study or Trial ; Allergan: Consultant or Advisor,Meeting Participant or Lecturer,Scientific Study or Trial ; American Medical Systems: Consultant or Advisor,Scientific Study or Trial ; Lilly: Consultant or Advisor

Medical Treatment Using Antimuscarinics in the Male-Rescue Therapy or More?

Christopher Chapple, BSc, MD, FRCS (Urol)


PDE 5 inhibitors and LUTS Cialis 5 mg daily and its new indication for BPH and BPH/ED

Claus G. Roehrborn, MD

Medical Treatment Using Antimuscarinics in the Male – Rescue Therapy or More?


Andersson KE, Chapple CR et al. Urol 2012

Chapple CR et al. Eur Urol 2006;49:651–9

Chapple CR et al. Int J Clin Pract 2006; 60: 959–966

Helfand BT et al. J Urol 2009;181 (4 Suppl):702 (abs. 1942)

Irwin DE et al. Eur Urol. 2006; 50:1306–15

Knutson T et al. Neurourol Urodyn 2001;20:237–47

Milsom I et al. BJU Int 2001;87:760–766

Sexton CC et al BJU Int 2009;103(Suppl3):12–23

Speakman MJ. Eur Urol Suppl 2008;7:680–9

Van Kerrebroeck P et al. Eur Urol Suppl 2005; 4: 61 (abstract 233)

PDE 5 Inhibitors and LUTS Cialis 5 mg daily And its new indicationFor BPH and BPH/ED


Broderick Urology 2010 Jun;75(6):1452–8

Feldman et al. J Urol 1994;151:54–61

Roehrborn et al J Urol 2008 Oct;180(4):1228–34

Rosen R, et al. Eur Urol 2003;44:637–649

ADVERTISEMENT

ADVERTISEMENT
Donate
Contact
Press/Media
Sections
Term of Use
Site Map


ADVERTISEMENT